Louisville, CO, United States of America

Allison L Marlow

This inventor holds 26 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in MEK Inhibitors. Top assignees: Array Biopharma Inc., Genentech, Inc., Astrazeneca Ab. Active years: 2007-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Allison L Marlow. Retrieved from https://idiyas.com/inventor/allison-l-marlow

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 6)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 12 (Patent Applications = 6)

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 166(Granted Patents)

Location History:

Louisville, CO (US) (2007 - 2013)
Boulder, CO (US) (2008 - 2015)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2007-2015

Loading Chart...

Areas of Expertise:

Serine/Threonine Kinase

MEK Inhibitors

Heterocyclic Compounds

Dihydropyridine Derivatives

Benzimidazole Derivatives

Hyperproliferative Disorders

Crystalline Forms

Inflammatory Diseases

Substituted Pyridazines

Heterobicyclic Thiophene

Heterobicyclic Pyrazole

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9133187 - Serine/threonine kinase inhibitors (2015-09-15),

2. 8513293 - Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal (2013-08-20),

3. 8299076 - Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (2012-10-30),

4. 8211921 - Heterocyclic inhibitors of MEK and methods of use (2012-07-03),

5. 8211920 - 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof (2012-07-03),

6. 8193231 - Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof (2012-06-05),

7. 8193230 - Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof (2012-06-05),

8. 8193229 - Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors (2012-06-05),

9. 8178693 - N3 alkylated benzimidazole derivatives as MEK inhibitors (2012-05-15),

10. 8101639 - 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof (2012-01-24),

11. 8101611 - Substituted pyridazines inhibitors of MEK (2012-01-24),

12. 8003805 - N3 alkylated benzimidazole derivatives as MEK inhibitors (2011-08-23),

13. 8003662 - Heterobicyclic thiophene compounds and methods of use (2011-08-23),

14. 7973170 - N3 alkylated benzimidazole derivatives as MEK inhibitors (2011-07-05),

15. 7893065 - Heterocyclic inhibitors of MEK and methods of use thereof (2011-02-22),

Title: Innovations in Oncology: The Work of Allison L. Marlow

Introduction

Allison L. Marlow is a distinguished inventor based in Louisville, CO, with a remarkable portfolio of 26 patents. His groundbreaking work primarily focuses on developing innovative treatments for hyperproliferative disorders, making significant strides in the field of oncology.

Latest Patents

Among his latest contributions to the field, Marlow has developed serine/threonine kinase inhibitors designed to target specific compounds that inhibit ERK kinase. These inhibitors exhibit potential for treating hyperproliferative disorders. He has also disclosed methods for treating such disorders or inhibiting cell growth in mammals. This includes the use of a pharmaceutical composition consisting of 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof, in combination with effective anti-tumor agents or radiation therapy.

Career Highlights

Marlow's career is marked by his involvement with renowned companies such as Array Biopharma Inc. and Genentech, Inc. His innovative spirit has driven advancements in drug development and therapeutic strategies, positioning him as a notable figure in biomedical research.

Collaborations

Throughout his career, Marlow has had the opportunity to collaborate with esteemed colleagues, including Eli M. Wallace and Joseph P. Lyssikatos. These collaborations have fostered a rich exchange of ideas and expertise, further enhancing his contributions to medical science.

Conclusion

Allison L. Marlow continues to advance the frontier of medical innovations, particularly in the treatment of hyperproliferative disorders. His commitment to research and development exemplifies the impact one inventor can have in transforming healthcare and improving patient outcomes.

Profile summary based on public USPTO records.